Catalyst Pharmaceuticals Inc (CPRX) Q4 2018 Earnings Conference Call Transcript

Image source: The Motley Fool.

Catalyst Pharmaceuticals Inc  (NASDAQ:CPRX)Q4 2018 Earnings Conference CallMarch 19, 2019, 8:30 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Greetings and welcome to the Catalyst Pharmaceuticals' Fourth Quarter and Year End 2018 Financial Results Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Ms. Ali Grande, Chief Financial Officer for Catalyst Pharmaceuticals. Thank you. You may begin.

Alicia Grande -- Vice President, Chief Financial Officer and Treasurer

Good morning, everyone. Thanks for joining our conference call. On today's call we have Pat McEnany, Chairman and Chief Executive Officer; Dr. Steve Miller, Chief Operating Officer and Chief Scientific Officer; and Dan Brennan, Chief Commercial Officer. Before we begin, I would like to remind you that in the following comments and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of the federal securities laws.

These statements relate to our current expectations, estimates and projections, and are not guarantees of future performance. They involve risk, uncertainties and assumptions that are difficult to predict, and which may prove not to be accurate. Actual results may vary. These forward-looking statements should be considered only in conjunction with the detailed information contained in our SEC filings, including the risk factors in our annual report on Form 10-K.

At this time, I'll turn the call over to Pat.

Patrick J. McEnany -- Co-Founder, Chairman, President and Chief Executive Officer

Thank you, Ali. Good morning, everyone, and thank you for joining us today. 2018 was a pivotal year for Catalyst that culminated in the approval of Firdapse, which was commercially launched on January 15th. This was also a transformational year for adult patients in the United States, who struggled with the debilitating effects of Lambert-Eaton Myasthenic Syndrome or LEMS. Prior to the approval of Firdapse, these patients had no evidence-based treatment option that was approved for use. Furthermore, only a small number of LEMS patients had access to any treatment at all in the form of an unapproved investigational amifampridine treatment.

I'd like to focus my remarks today on our three strategic priorities. First, and most importantly, the successful execution of the Firdapse launch